TABLE 1.

Clinicopathological characteristics of LUSC patients from TCGA and GEO cohorts.

Characteristics	TCGA training set (n = 339)	TCGA testing set (n = 144)	GSE37745 (n = 66)	GSE30219 (n = 61)
TNM stage
Stage I	178 (52.51%)	64 (44.44%)	40 (60.6%)	—
Stage II	111 (32.74%)	47 (32.64%)	15 (22.73%)	—
Stage III	50 (14.75%)	33 (22.92%)	11 (16.67%)	—
Pathologic N
N0	221 (65.19%)	89 (61.81%)	—	—
N1	89 (26.25%)	35 (24.31%)	—	—
N2	21 (6.19%)	18 (12.5%)	—	—
N3	4 (1.18%)	1 (0.69%)	—	—
Nx	4 (1.18%)	1 (0.69%)	—	—
Pathologic T
T1	84 (24.78%)	30 (20.83%)	—	49 (80.32%)
T2	195 (57.52%)	86 (59.72%)	—	6 (9.84%)
T3	46 (13.57%)	22 (15.28%)	—	4 (6.56%)
T4	14 (4.13%)	6 (4.17%)	—	2 (3.28%)
Age
≤65	127 (37.47%)	60 (41.67%)	29 (43.94%)	36 (59.02%)
>65	212 (62.53%)	84 (58.33%)	37 (56.06%)	25 (40.98%)
Gender
Female	86 (25.37%)	41 (28.47%)	20 (30.3%)	5 (8.2%)
Male	253 (74.63%)	103 (71.53%)	46 (69.7%)	56 (91.8%)
Smoking history
No	48 (14.16%)	25 (17.36%)	—	—
Yes	291 (85.84%)	119 (82.64%)	—	—